SVFCX vs. DOCU, NICE, ESTC, MNDY, TWLO, CYBR, PCOR, GWRE, PAYC, and DUOL
Should you be buying Smead Value C stock or one of its competitors? The main competitors of Smead Value C include DocuSign (DOCU), NICE (NICE), Elastic (ESTC), monday.com (MNDY), Twilio (TWLO), CyberArk Software (CYBR), Procore Technologies (PCOR), Guidewire Software (GWRE), Paycom Software (PAYC), and Duolingo (DUOL).
Smead Value C (NASDAQ:SVFCX) and DocuSign (NASDAQ:DOCU) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.
Smead Value C has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, DocuSign has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
In the previous week, DocuSign had 46 more articles in the media than Smead Value C. MarketBeat recorded 46 mentions for DocuSign and 0 mentions for Smead Value C. DocuSign's average media sentiment score of 0.34 beat Smead Value C's score of 0.00 indicating that DocuSign is being referred to more favorably in the news media.
DocuSign has a consensus target price of $59.36, suggesting a potential upside of 14.05%. Given DocuSign's higher possible upside, analysts clearly believe DocuSign is more favorable than Smead Value C.
DocuSign received 412 more outperform votes than Smead Value C when rated by MarketBeat users. However, 100.00% of users gave Smead Value C an outperform vote while only 59.31% of users gave DocuSign an outperform vote.
DocuSign has a net margin of 3.81% compared to Smead Value C's net margin of 0.00%. DocuSign's return on equity of 16.06% beat Smead Value C's return on equity.
DocuSign has higher revenue and earnings than Smead Value C.
60.2% of Smead Value C shares are owned by institutional investors. Comparatively, 77.6% of DocuSign shares are owned by institutional investors. 10.3% of Smead Value C shares are owned by insiders. Comparatively, 1.7% of DocuSign shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
DocuSign beats Smead Value C on 12 of the 14 factors compared between the two stocks.
Get Smead Value C News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVFCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVFCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SVFCX vs. The Competition
Smead Value C Competitors List
Related Companies and Tools
